9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma

Aaron M. Teitelbaum, Jose L. Gallardo, Jessica Bedi, Rajan Giri, Adam R. Benoit, Michael R Olin, Kate M. Morizio, John R. Ohlfest, Rory P Remmel, David M Ferguson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: The delivery of drugs to the brain is a major obstacle in the design and development of useful treatments for malignant glioma. Previous studies by our laboratory have identified a series of 9-amino acridine compounds that block the catalytic cycle of topoisomerase II resulting in apoptosis and cell death in a variety of cancer cell lines. Methods: This study reports the in vitro and in vivo activity of two promising lead compounds, [{9-[2-(1H-Indol-3-yl)- ethylamino]-acridin-4-yl}-(4-methyl-piperazin-1-yl)- methanone (1) and [9-(1-Benzyl-piperidin-4-ylamino)-acridin- 3-yl]-(4-methyl-piperazin-1-yl)-methanone] (2), using an orthotopic glioblastoma mouse model. In addition, the absorption, distribution, and metabolism properties are characterized by determining metabolic stability, MDCK accumulation, Pgp efflux transport, plasma protein binding, and brain distribution in mouse pharmacokinetic studies. Results: The efficacy results indicate low micromolar ED50 values against glioma cells and a significant increase in the survival of glioma-bearing mice dosed with (2) (p < 0.05). Pharmacokinetic data collected at time intervals following a 60 mg/kg oral dose of acridine 1 and 2 showed both compounds penetrate the blood-brain barrier yielding peak concentrations of 0.25 μM and 0.6 μM, respectively. Peak plasma concentrations were determined to be 2.25 μM (1) and 20.38 μM (2). The results were further compared with data collected using a 15 mg/kg intravenous dose of 2 which yielded a peak concentration in the brain of 1.7 μM at 2.0 h relative to a 2.04 μM peak plasma concentration. The bioavailability was calculated to be 83.8%. Conclusion: Taken overall, the results suggest compounds in this series may offer new strategies for the design of chemotherapeutics for treating brain cancers with high oral bioavailability and improved efficacy.

Original languageEnglish (US)
Pages (from-to)1519-1527
Number of pages9
JournalCancer chemotherapy and pharmacology
Volume69
Issue number6
DOIs
StatePublished - Jun 1 2012

Fingerprint

Acridines
Pharmacokinetics
Glioma
Brain
Biological Availability
Type II DNA Topoisomerase
Bearings (structural)
Glioblastoma
Lead compounds
Blood-Brain Barrier
Plasmas
Protein Binding
Brain Neoplasms
Blood Proteins
Carrier Proteins
Cell Death
Cell death
Metabolism
Apoptosis
Cell Line

Keywords

  • Acridine
  • Anticancer agents
  • Glioma
  • In vivo efficacy
  • Pharmacokinetics
  • Topoisomerase

Cite this

9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma. / Teitelbaum, Aaron M.; Gallardo, Jose L.; Bedi, Jessica; Giri, Rajan; Benoit, Adam R.; Olin, Michael R; Morizio, Kate M.; Ohlfest, John R.; Remmel, Rory P; Ferguson, David M.

In: Cancer chemotherapy and pharmacology, Vol. 69, No. 6, 01.06.2012, p. 1519-1527.

Research output: Contribution to journalArticle

Teitelbaum, Aaron M. ; Gallardo, Jose L. ; Bedi, Jessica ; Giri, Rajan ; Benoit, Adam R. ; Olin, Michael R ; Morizio, Kate M. ; Ohlfest, John R. ; Remmel, Rory P ; Ferguson, David M. / 9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma. In: Cancer chemotherapy and pharmacology. 2012 ; Vol. 69, No. 6. pp. 1519-1527.
@article{9f8815e55ecf4d05947c5f237d60c4ee,
title = "9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma",
abstract = "Purpose: The delivery of drugs to the brain is a major obstacle in the design and development of useful treatments for malignant glioma. Previous studies by our laboratory have identified a series of 9-amino acridine compounds that block the catalytic cycle of topoisomerase II resulting in apoptosis and cell death in a variety of cancer cell lines. Methods: This study reports the in vitro and in vivo activity of two promising lead compounds, [{9-[2-(1H-Indol-3-yl)- ethylamino]-acridin-4-yl}-(4-methyl-piperazin-1-yl)- methanone (1) and [9-(1-Benzyl-piperidin-4-ylamino)-acridin- 3-yl]-(4-methyl-piperazin-1-yl)-methanone] (2), using an orthotopic glioblastoma mouse model. In addition, the absorption, distribution, and metabolism properties are characterized by determining metabolic stability, MDCK accumulation, Pgp efflux transport, plasma protein binding, and brain distribution in mouse pharmacokinetic studies. Results: The efficacy results indicate low micromolar ED50 values against glioma cells and a significant increase in the survival of glioma-bearing mice dosed with (2) (p < 0.05). Pharmacokinetic data collected at time intervals following a 60 mg/kg oral dose of acridine 1 and 2 showed both compounds penetrate the blood-brain barrier yielding peak concentrations of 0.25 μM and 0.6 μM, respectively. Peak plasma concentrations were determined to be 2.25 μM (1) and 20.38 μM (2). The results were further compared with data collected using a 15 mg/kg intravenous dose of 2 which yielded a peak concentration in the brain of 1.7 μM at 2.0 h relative to a 2.04 μM peak plasma concentration. The bioavailability was calculated to be 83.8{\%}. Conclusion: Taken overall, the results suggest compounds in this series may offer new strategies for the design of chemotherapeutics for treating brain cancers with high oral bioavailability and improved efficacy.",
keywords = "Acridine, Anticancer agents, Glioma, In vivo efficacy, Pharmacokinetics, Topoisomerase",
author = "Teitelbaum, {Aaron M.} and Gallardo, {Jose L.} and Jessica Bedi and Rajan Giri and Benoit, {Adam R.} and Olin, {Michael R} and Morizio, {Kate M.} and Ohlfest, {John R.} and Remmel, {Rory P} and Ferguson, {David M}",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s00280-012-1855-5",
language = "English (US)",
volume = "69",
pages = "1519--1527",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - 9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma

AU - Teitelbaum, Aaron M.

AU - Gallardo, Jose L.

AU - Bedi, Jessica

AU - Giri, Rajan

AU - Benoit, Adam R.

AU - Olin, Michael R

AU - Morizio, Kate M.

AU - Ohlfest, John R.

AU - Remmel, Rory P

AU - Ferguson, David M

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Purpose: The delivery of drugs to the brain is a major obstacle in the design and development of useful treatments for malignant glioma. Previous studies by our laboratory have identified a series of 9-amino acridine compounds that block the catalytic cycle of topoisomerase II resulting in apoptosis and cell death in a variety of cancer cell lines. Methods: This study reports the in vitro and in vivo activity of two promising lead compounds, [{9-[2-(1H-Indol-3-yl)- ethylamino]-acridin-4-yl}-(4-methyl-piperazin-1-yl)- methanone (1) and [9-(1-Benzyl-piperidin-4-ylamino)-acridin- 3-yl]-(4-methyl-piperazin-1-yl)-methanone] (2), using an orthotopic glioblastoma mouse model. In addition, the absorption, distribution, and metabolism properties are characterized by determining metabolic stability, MDCK accumulation, Pgp efflux transport, plasma protein binding, and brain distribution in mouse pharmacokinetic studies. Results: The efficacy results indicate low micromolar ED50 values against glioma cells and a significant increase in the survival of glioma-bearing mice dosed with (2) (p < 0.05). Pharmacokinetic data collected at time intervals following a 60 mg/kg oral dose of acridine 1 and 2 showed both compounds penetrate the blood-brain barrier yielding peak concentrations of 0.25 μM and 0.6 μM, respectively. Peak plasma concentrations were determined to be 2.25 μM (1) and 20.38 μM (2). The results were further compared with data collected using a 15 mg/kg intravenous dose of 2 which yielded a peak concentration in the brain of 1.7 μM at 2.0 h relative to a 2.04 μM peak plasma concentration. The bioavailability was calculated to be 83.8%. Conclusion: Taken overall, the results suggest compounds in this series may offer new strategies for the design of chemotherapeutics for treating brain cancers with high oral bioavailability and improved efficacy.

AB - Purpose: The delivery of drugs to the brain is a major obstacle in the design and development of useful treatments for malignant glioma. Previous studies by our laboratory have identified a series of 9-amino acridine compounds that block the catalytic cycle of topoisomerase II resulting in apoptosis and cell death in a variety of cancer cell lines. Methods: This study reports the in vitro and in vivo activity of two promising lead compounds, [{9-[2-(1H-Indol-3-yl)- ethylamino]-acridin-4-yl}-(4-methyl-piperazin-1-yl)- methanone (1) and [9-(1-Benzyl-piperidin-4-ylamino)-acridin- 3-yl]-(4-methyl-piperazin-1-yl)-methanone] (2), using an orthotopic glioblastoma mouse model. In addition, the absorption, distribution, and metabolism properties are characterized by determining metabolic stability, MDCK accumulation, Pgp efflux transport, plasma protein binding, and brain distribution in mouse pharmacokinetic studies. Results: The efficacy results indicate low micromolar ED50 values against glioma cells and a significant increase in the survival of glioma-bearing mice dosed with (2) (p < 0.05). Pharmacokinetic data collected at time intervals following a 60 mg/kg oral dose of acridine 1 and 2 showed both compounds penetrate the blood-brain barrier yielding peak concentrations of 0.25 μM and 0.6 μM, respectively. Peak plasma concentrations were determined to be 2.25 μM (1) and 20.38 μM (2). The results were further compared with data collected using a 15 mg/kg intravenous dose of 2 which yielded a peak concentration in the brain of 1.7 μM at 2.0 h relative to a 2.04 μM peak plasma concentration. The bioavailability was calculated to be 83.8%. Conclusion: Taken overall, the results suggest compounds in this series may offer new strategies for the design of chemotherapeutics for treating brain cancers with high oral bioavailability and improved efficacy.

KW - Acridine

KW - Anticancer agents

KW - Glioma

KW - In vivo efficacy

KW - Pharmacokinetics

KW - Topoisomerase

UR - http://www.scopus.com/inward/record.url?scp=84863802073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863802073&partnerID=8YFLogxK

U2 - 10.1007/s00280-012-1855-5

DO - 10.1007/s00280-012-1855-5

M3 - Article

C2 - 22402637

AN - SCOPUS:84863802073

VL - 69

SP - 1519

EP - 1527

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -